{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:59:23Z","timestamp":1782197963091,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T00:00:00Z","timestamp":1520208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2018.01.057","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T12:57:16Z","timestamp":1526993836000},"page":"4806-4815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"PA","title":["Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs"],"prefix":"10.1016","volume":"36","author":[{"given":"Lauri E.","family":"Markowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Drolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2018.01.057_b0005","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2018.01.057_b0010","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.vaccine.2018.01.057_b0015","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1080\/21645515.2015.1050570","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9\u201314 years: Results to month 12 from a randomized trial","volume":"11","author":"Leung","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"22","key":"10.1016\/j.vaccine.2018.01.057_b0020","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.vaccine.2018.01.057_b0025","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"43","key":"10.1016\/j.vaccine.2018.01.057_b0030","first-page":"465","article-title":"Human papillomavirus vaccines: WHO position paper, October 2014","volume":"89","author":"WHO","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"49","key":"10.1016\/j.vaccine.2018.01.057_b0035","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"10.1016\/j.vaccine.2018.01.057_b0040","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.vaccine.2017.03.096","article-title":"Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis","volume":"35","author":"D'Addario","year":"2017","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.057_b0045","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1038\/bjc.2014.198","article-title":"Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16\/18 and closely related HPV types","volume":"110","author":"Kavanagh","year":"2014","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.057_b0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/bjc.2016.97","article-title":"Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis","volume":"114","author":"Cuschieri","year":"2016","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.057_b0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jama.2014.95","article-title":"Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma","volume":"311","author":"Herweijer","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2018.01.057_b0060","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/cid\/civ364","article-title":"Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550 000 young girls","volume":"61","author":"Blomberg","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.01.057_b0065","doi-asserted-by":"crossref","first-page":"e0132404","DOI":"10.1371\/journal.pone.0132404","article-title":"Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study","volume":"10","author":"Dominiak-Felden","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.057_b0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/OLQ.0000000000000615","article-title":"Impact of number of human papillomavirus vaccine doses on genital warts diagnoses among a national cohort of U.S. adolescents","volume":"44","author":"Perkins","year":"2017","journal-title":"Sex Transm Dis"},{"issue":"25","key":"10.1016\/j.vaccine.2018.01.057_b0075","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.vaccine.2017.04.080","article-title":"Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain","volume":"35","author":"Navarro-Illana","year":"2017","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.057_b0080","doi-asserted-by":"crossref","first-page":"e015021","DOI":"10.1136\/bmjopen-2016-015021","article-title":"Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study","volume":"7","author":"Lamb","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2018.01.057_b0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2018.01.057_b0090","doi-asserted-by":"crossref","first-page":"g1458","DOI":"10.1136\/bmj.g1458","article-title":"Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia","volume":"348","author":"Crowe","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.01.057_b0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pvr.2015.05.005","article-title":"Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia","volume":"1","author":"Brotherton","year":"2015","journal-title":"Papillomavrius Res"},{"issue":"5","key":"10.1016\/j.vaccine.2018.01.057_b0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jamapediatrics.2015.3926","article-title":"Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females","volume":"170","author":"Hofstetter","year":"2016","journal-title":"JAMA Pediatr"},{"issue":"12","key":"10.1016\/j.vaccine.2018.01.057_b0105","doi-asserted-by":"crossref","first-page":"E281","DOI":"10.1503\/cmaj.151528","article-title":"Effect of human papillomavirus vaccination on cervical cancer screening in Alberta","volume":"188","author":"Kim","year":"2016","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.vaccine.2018.01.057_b0110","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1016\/j.vaccine.2018.01.057_b0115","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.vaccine.2015.01.084","article-title":"Reduction in HPV 16\/18-associated high grade cervical lesions following HPV vaccine introduction in the United States \u2013 2008\u20132012","volume":"33","author":"Hariri","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T06:17:28Z","timestamp":1561529848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18301178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":23,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X18301178"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}